Sentinel Lymph Node Biopsy in Breast Cancer Patients by Means of Indocyanine Green Using the Karl Storz VITOM® Fluorescence Camera

Currently, the use of radioisotope and blue dye for sentinel lymph node biopsy (SLNB) for axillary staging in breast cancer is common. Recently, indocyanine green (ICG) has been proposed as an alternative sentinel lymph node (SLN) tracking agent. We evaluated the clinical value of ICG as an addition...

Descripción completa

Detalles Bibliográficos
Autores principales: Papathemelis, Thomas, Jablonski, Evi, Scharl, Anton, Hauzenberger, Tanja, Gerken, Michael, Klinkhammer-Schalke, Monika, Hipp, Matthias, Scharl, Sophia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892256/
https://www.ncbi.nlm.nih.gov/pubmed/29780827
http://dx.doi.org/10.1155/2018/6251468
Descripción
Sumario:Currently, the use of radioisotope and blue dye for sentinel lymph node biopsy (SLNB) for axillary staging in breast cancer is common. Recently, indocyanine green (ICG) has been proposed as an alternative sentinel lymph node (SLN) tracking agent. We evaluated the clinical value of ICG as an additional tracer in combination with Technetium(99m) and as an alternative to Technetium(99m) for the identification of SLN in 104 breast cancer patients. 21 patients had at least 1 histologically tumor-positive SLN. All 21 patients were detected by ICG; in one of these 21 sentinel-positive patients, Technetium(99m) was unable to identify lymph node involvement. Our results show that ICG is as effective as the radioisotope for SLNB. In addition, as a near-infrared dye, it has the advantages of real-time visualization, lower cost, and wider availability, since no radioactive material needs to be handled. This trial is registered with German Clinical Trial Register Main ID: DRKS00013606.

Ejemplares similares